|
Gastrointestinal Stromal Tumors
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Chronic otitis media
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Lymphadenopathy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Recurrent bronchitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Posterior pharyngeal cleft
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Elevated hepatic transaminase
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Failure to thrive in infancy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Restrictive ventilatory defect
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Decreased antibody level in blood
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
As malignant cell apoptosis is strongly enhanced by secondary oligomerization of TRAIL, we tested the hypothesis that soluble Fn14·TRAIL can be oligomerized and become more active by adding TWEAK, a cytokine secreted in the tumor environment.
|
28455246 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Pharmacokinetics of RG7212 and dynamics of TWEAK were determined, as were changes in tumor TWEAK-Fn14 signaling in paired pre- and posttreatment tumor biopsies.
|
26446946 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
This was further supported by decreased gene expression of extracellular matrix-degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), pro-inflammatory mediators of the metastasis-promoting tumor microenvironment (TNFSF12, IL6, ANGPTL2, CSF1R) and concomitant increased expression of the validated breast cancer metastasis suppressor gene (BRMS1).
|
24498382 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Both GrB-TWEAK and GrB-Fc-IT4 displayed significant tumor growth inhibition when administered to mice bearing orthotopic MDA-MB-231 (TNBC) tumor xenografts.
|
25239934 |
2014 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The TWEAK:Fn14 signaling axis promotes tumor cell proliferation and tumor angiogenesis, while TRAIL:TRAIL-receptor (TRAIL-R) interactions selectively induce apoptosis in malignant cells.
|
24130833 |
2013 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) receptor Fn14 (TNFRSF12A) is expressed at low levels in normal tissues but frequently highly expressed in a wide range of tumor types such as lung, melanoma, and breast, and therefore it is a potentially unique therapeutic target for these diverse tumor types.
|
23722548 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
These factors and TWEAK-induced signaling were decreased, and tumor, blood, and spleen immune cell composition was altered with RG7212 treatment in mice.
|
23974006 |
2013 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, an anti-Fn14 mAb that blocks TWEAK-Fn14 interaction could totally abrogate TWEAK binding and TWEAK-induced cell death in all TWEAK-sensitive tumor cell lines.
|
12496418 |
2003 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
TWEAK, a new member of the tumor necrosis factor (TNF) family, induces cell death in some tumor cell lines, but its physiological functions are largely unknown.
|
11067885 |
2000 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
Nilotinib ameliorates folic acid-induced acute kidney injury through modulation of TWEAK and HSP-70 pathways.
|
31593741 |
2019 |
|
Kidney Failure, Acute
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have now explored the cell death pathways induced by TWEAK/Fn14 activation and their relevance during AKI.
|
29588419 |
2018 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
By reviewing the literature, this article assesses the role of this pathway in lupus nephritis, underlines the importance of TWEAK in urine (uTWEAK) as a biomarker of the disease and stresses the favourable results published in the literature from the inhibition of the TWEAK/Fn14 pathway as a therapeutic target in experimental animal models, demonstrating its potential application in other settings.
|
27595519 |
2018 |
|
Lupus Nephritis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study.
|
29668584 |
2018 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Soluble TWEAK serum concentration was measured in 702 CKD patients without any previous CV event from The National Observatory of Atherosclerosis in Nephrology (NEFRONA) Study.
|
28390291 |
2017 |
|
Arteriosclerosis
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Genetic inactivation of Tnfsf12 reduced atherosclerosis extension and severity in diabetic ApoE deficient mice.
|
28447667 |
2017 |